This study confirmed the PI3K/AKT/mTOR pathway and PIK3CA as an effective target for breast cancer therapy and introduced BJ-derived exosomes as a promising nanocarrier for siRNA delivery. This evidence concerns the gene PIK3CA and breast carcinoma.